Renin–angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice

Moises Auron,1,2 Brian Harte,1 Ajay Kumar,1 Franklin Michota1

1Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio, USA
2Center for Pediatric Hospital Medicine, Children’s Hospital, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence to Moises Auron, Department of Hospital Medicine, Cleveland Clinic, 9500 Euclid Ave, M2 Annex, Cleveland, OH 44195, USA; auromm@ccf.org

Received 28 October 2010
Accepted 21 February 2011
Published Online First 25 March 2011

ABSTRACT
There are no existing guidelines supporting the withdrawal or continuation of renin–angiotensin–aldosterone system (RAAS) antagonists in the perioperative setting. RAAS antagonists include ACE inhibitors, angiotensin II receptor subtype 1 blockers and direct renin inhibitors (eg, aliskiren), as well as the aldosterone antagonists. The use of these agents before surgery has been associated with a variable incidence of hypotension during the initial 30 min after induction of anaesthesia; however, these hypotensive episodes have not been conclusively linked to any significant postoperative complications, although recent data suggest an increase in postoperative morbidity and mortality in patients undergoing coronary artery bypass grafting. Further studies are required to be able to demonstrate if the organ-protective benefits of RAAS antagonists justify their continuation in the perioperative setting. Temporary withdrawal of RAAS antagonists in these patients may prevent or attenuate intraoperative hypotension and hypovolaemia. Alternatively, the increase in RAAS activity and blood pressure expected with cessation of RAAS antagonist therapy may impair regional circulation secondary to an increase in systemic vascular resistance. Full discussion of the potential implications of perioperative RAAS antagonist therapy with the surgical team is important, and strategies to ensure careful monitoring and maintenance of adequate intravascular volume before induction of anaesthesia are essential.

INTRODUCTION
The renin–angiotensin–aldosterone system (RAAS) antagonists include ACE inhibitors (ACEIs), angiotensin II receptor subtype 1 blockers (ARBs) and direct renin inhibitors (eg, aliskiren). The use of these agents has increased substantially in the past two decades, and they currently are among the most commonly used and effective treatments for hypertension,1 congestive heart failure,2 coronary artery disease3 and diabetic nephropathy.4 5 As a result, many contemporary surgical patients will be using RAAS antagonists before their procedure, and questions remain as to the potential risks and/or benefits of continuing these agents in the immediate perioperative period.

There have been several reports and small studies suggesting that intraoperative hypotension after the induction of anaesthesia is more common in patients who receive RAAS antagonist therapy on the day of surgery.6 Similar reports have linked postoperative acute renal failure with RAAS antagonist use before surgery, which is related to both intraoperative hypotension and use of inotropes.7 8 Although most of the existing literature has not associated the perioperative use of these agents with an increase in short- or long-term mortality, one recent analysis has found a higher incidence of postoperative atrial fibrillation (POAF), use of inotropes, and death with preoperative RAAS antagonist therapy.8

The available literature on this topic is scant, and no guidelines have yet been published on the appropriate use of RAAS antagonists in the surgical patient. In addition, the introduction of new agents that modulate RAAS, such as the direct renin inhibitor aliskiren, will add further complexity to this important clinical question. The purpose of this review is to compare and contrast the existing literature supporting the use or cessation of RAAS antagonists in both cardiac and non-cardiac surgery patients, and to provide further insight for the clinician caring for such patients in the perioperative period.

PHARMACOLOGICAL PROPERTIES AND PERIOPERATIVE IMPLICATIONS
The vasodilatory actions of RAAS antagonists involve multiple mechanisms (tables 1 and 2). These include direct sympathetic blockade, increased bioavailability of vasodilators such as bradykinin, nitric oxide and prostacyclins, inhibition of the direct and indirect vasoconstrictor effects of angiotensin II, and reduced secretion of aldosterone and antidiuretic hormone resulting in a decrease in salt and water reabsorption by the kidney.14 15 Given the wide distribution of ACE in the body, the RAAS antagonists have wide-ranging effects, inhibiting various angiotensin peptides as well as both renin and pro-renin receptors with subsequent endocrine, paracrine and intracrine functions, which in turn regulate diverse physiological functions (figure 1).12 13 There are well-defined deleterious effects of chronic RAAS stimulation such as upregulation of angiotensin 1 receptor, subsequent aldosterone release, and the promotion of vascular hypertrophy, fibrosis and proliferation. There are also novel components of the RAAS that exert unclear effects, such as a homologue of ACE called ACE 2, which mediates the formation of the heptapeptide Ang1–7, a peptide with both vasodilatory and vascular endothelial anti-inflammatory properties.14 15 The RAAS, along with sympathetic nervous system activation and arginine–vasopressin (AVP) release, is a primary mechanism for the maintenance of
and its expression (DD allele) has been postulated to offer increased ACE concentrations in plasma and at the tissue level, 16 of the ACE gene. The D allele has been associated with the insertion/deletion polymorphism; this is based on the presence of the ACE (splanchnic).

Table 2 Pharmacology of angiotensin receptor II type 1 blockers

<table>
<thead>
<tr>
<th>Active metabolite</th>
<th>Zinc ligand</th>
<th>Bioavailability (%)</th>
<th>Half-life (h)</th>
<th>Route of elimination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril</td>
<td>No</td>
<td>Sulphhydryl</td>
<td>75–91</td>
<td>1.7</td>
</tr>
<tr>
<td>Enalapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>60</td>
<td>11</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>No</td>
<td>Carboxyl</td>
<td>6–60</td>
<td>12</td>
</tr>
<tr>
<td>Benazepril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>&gt;37</td>
<td>10–11</td>
</tr>
<tr>
<td>Quinapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>&gt;60</td>
<td>1.9–2.5 (25 terminal)</td>
</tr>
<tr>
<td>Ramipril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>50–60</td>
<td>Triphasic 4, 9–18, &gt;50</td>
</tr>
<tr>
<td>Trandolapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>70</td>
<td>15–24</td>
</tr>
<tr>
<td>Moexipril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>13</td>
<td>2–9</td>
</tr>
<tr>
<td>Fosinopril</td>
<td>Yes</td>
<td>Phosphinyl</td>
<td>36</td>
<td>12</td>
</tr>
</tbody>
</table>

Adapted from Brown and Vaughan.9

Venous return and systemic blood pressure (SBP) during periods of acute haemodynamic stress such as the induction of anaesthesia. Angiotensin II is a potent direct vasoconstrictor and physiological stimulus for AVP release, and counter-regulates the usual hypotensive effect of anaesthetic agents on the sympathetic nervous system (increased venous pooling of blood, decreased cardiac output, and arterial hypotension). As a result, patients chronically treated with RAAS antagonists are potentially at higher risk of developing clinically significant hypotension after the induction of anaesthesia because of the decreased vascular resistance and associated decreased cardiac filling.6 16 17 The withdrawal of these agents should reduce the hypotensive episodes, but may also increase systemic vascular resistance, which can compromise regional circulation (splanchinic).

Because the RAAS interacts at multiple levels to maintain intraoperative blood pressure (BP), the successful treatment of intraoperative hypotension in the setting of RAAS blockade includes adequate intravascular volume repletion, as well as the use of AVP agonists (terlipressin, vasopressin) and adrenergic agonists. In the USA, vasopressin is the only available AVP agonist.18 AVP agonists potentiate the response to endogenous catecholamines, which increases vascular resistance and venous return and improves myocardial oxygen delivery and cardiac contractility.19

Complicating matters further, recent pharmacogenomic studies of the RAAS have demonstrated variable genetic susceptibility to RAAS antagonists via single-nucleotide polymorphisms in the genes that encode angiotensinogen, angiotensin receptor 1 and angiotensin receptor 2.20 21 The most comprehensively studied RAAS polymorphism is the ACE insertion/deletion polymorphism; this is based on the presence (I) or absence (D) of a 287 bp Alu repeat sequence within intron 16 of the ACE gene. The D allele has been associated with increased ACE concentrations in plasma and at the tissue level, and its expression (DD allele) has been postulated to offer resistance to ACE inhibitors and cause increased adverse cardiovascular and renal effects.22 23 Thus the haemodynamic response to RAAS antagonists in the perioperative setting may be further influenced by individual genetics.

Table 1 Pharmacology of ACE inhibitors

<table>
<thead>
<tr>
<th>Active metabolite</th>
<th>Zinc ligand</th>
<th>Bioavailability (%)</th>
<th>Half-life (h)</th>
<th>Route of elimination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril</td>
<td>No</td>
<td>Sulphhydryl</td>
<td>75–91</td>
<td>1.7</td>
</tr>
<tr>
<td>Enalapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>60</td>
<td>11</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>No</td>
<td>Carboxyl</td>
<td>6–60</td>
<td>12</td>
</tr>
<tr>
<td>Benazepril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>&gt;37</td>
<td>10–11</td>
</tr>
<tr>
<td>Quinapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>&gt;60</td>
<td>1.9–2.5 (25 terminal)</td>
</tr>
<tr>
<td>Ramipril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>50–60</td>
<td>Triphasic 4, 9–18, &gt;50</td>
</tr>
<tr>
<td>Trandolapril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>70</td>
<td>15–24</td>
</tr>
<tr>
<td>Moexipril</td>
<td>Yes</td>
<td>Carboxyl</td>
<td>13</td>
<td>2–9</td>
</tr>
<tr>
<td>Fosinopril</td>
<td>Yes</td>
<td>Phosphinyl</td>
<td>36</td>
<td>12</td>
</tr>
</tbody>
</table>

Adapted from Brown and Vaughan.9

EVIDENCE AGAINST RAAS ANTAGONISTS IN THE PERIOPERATIVE SETTING

The current medication guideline used at the perioperative clinic in our institution recommends that both ACEIs and ARBs be discontinued on the morning of non-cardiac surgery.24 There are no national or international guidelines that delineate a standard of care in the use of these agents in the perioperative period. The literature supporting this practice relates to the frequency and degree of intraoperative hypotension observed with concomitant use of RAAS antagonists.

Non-cardiac surgery

The following studies focused on the effect on BP after intubation in patients taking ACEIs before surgery. McCarthy et al studied the effect of two doses of sublingual captopril (12.5 mg and 25 mg) versus placebo administered 25 min before tracheal intubation in 40 patients. The patients receiving captopril were more likely to develop hypotension than those receiving placebo (p<0.05) within 3 min of intubation; however, there was no significant difference between the two captopril doses.25 Coriat et al randomised 56 patients undergoing non-cardiac surgery chronically treated for hypertension with captopril (n=36) or enalapril (n=20) into two groups, one in which the ACEIs were administered on the morning of surgery and the other in which it was withdrawn. In the former group, all of the patients who received enalapril and 64% of those who received captopril required ephedrine to treat post-induction hypotension. The rate was significantly higher than in the patients whose ACEIs were withdrawn (enalapril 100% vs 18%, p<0.005; captopril 64% vs 21%, p<0.05).26

The difference in haemodynamic response between ACEIs and ARBs was demonstrated in a study by Brabant et al. Haemodynamic responses were evaluated in patients treated with β-adrenergic blockers (BBs) and/or calcium channel blockers (CCBs), ACEIs or ARBs after induction of anaesthesia. Hypotension was defined as an SBP decrease of >30% from the preoperative value or an absolute SBP decrease below 90 mm Hg. Hypotension occurred in 100% of patients receiving ARBs (12 out of 12), compared with 60% of BB/CC-treated patients (27 of 45) or with 66% of ACEI-treated patients (18 of 27) (p≤0.05). After induction of anaesthesia, the lowest mean arterial pressure (mm Hg) was 54±6 in the ARB group, 66±12 in the BB/CC group, and 68±10 in the ACEI group (p<0.001 comparing ARB with CC/BB or ACEI groups). The patients treated with ARBs...
required higher doses of adrenergic agents (ephedrine, phenylephrine) (4 of 12) compared with the BB/CB group (0 of 45) or the ACEI group (1 of 27); however, the hypotension was responsive to vasopressin agonists.27

Several studies have focused on the time that RAAS antagonists should be withheld before surgery. Bertrand et al studied 37 patients receiving chronic therapy with ARBs; 18 had their ARBs discontinued the day before surgery, and 19 received their ARB dose 1 h before induction of anaesthesia. He found that the administration of ARBs on the morning of surgery was associated with more frequent episodes of hypotension as well as longer duration of hypotension than if ARBs was withheld. In addition, the hypotensive episodes were refractory to initial therapy with adrenergic agents, requiring the addition of terlipressin. This study also found that the timing of the RAAS antagonist did play a role in the outcome. Patients that received an ARB dose within 10 h of anaesthesia induction were more likely to have hypotension than patients receiving the ARB dose more than 10 h before the induction of anaesthesia. The authors recommended discontinuing ARBs on the day before surgery.28

Comfere et al evaluated 267 patients receiving chronic antihypertensive treatment with ACEIs/ARBs undergoing general anaesthesia. The incidence of hypotension during the first 30 min after induction of anaesthesia was more common in patients whose most recent ACEIs/ARBs was taken <10 h compared with those who stopped it >10 h before induction (60% vs 46%, OR 1.74 (95% CI 1.03 to 2.93), p=0.04).29

Shirmer and Schurmann randomised 100 patients receiving chronic antihypertensive therapy with ACEIs in a double-blind study of ACEI discontinuation in non-cardiac surgery. Fifty patients were allocated to receive ACEIs on the morning of surgery and 50 to have it withdrawn. After induction of anaesthesia, the BP and heart rate were significantly lower in the group of patients receiving ACEIs than in the withdrawal group, and the use of supportive adrenergic agonists was required more often (17 of the 50 patients who took ACEIs versus five of the 50 patients in the withdrawal group, p<0.05). The authors concluded that patients chronically treated with ACEIs should receive the last dose on the day before surgery.30

The effect of sympathetic blockade of RAAS antagonists in the perioperative setting was evaluated by Licker et al, who compared in a prospective case–control study, the heart rate variability and baroreflex control before surgery and 30 min after induction of anaesthesia in two groups of patients with ischaemic heart disease undergoing non-cardiac surgery (16 receiving chronic ACEIs and 16 who did not) and found no

Figure 1  Renin—angiotensin—aldosterone system (RAAS) and site of action of the different RAAS antagonists. Note the pleiotropic effects of the RAAS that can be indirectly affected by the use of RAAS antagonists given its activity. Ang I—angiotensin 1 heptapeptide has similar activity to Ang II, as well as acts on angiotensin type 2 receptors. Ang IV—angiotensin 3–8 hexapeptide exerts its actions via insulin-regulated amino peptidase receptors (IRAP) with subsequent expression of inflammatory and immune mediators. Ang 1–9 (angiotensin 1–9 nanopeptide) is a precursor of Ang 1–7 via ACE 2 (homologue of ACE). Ang 1–7 (angiotensin 1–7 heptapeptide) acts via Mas receptors. Adapted from: Fyhrquist F, Saijonmaa O. Renin—angiotensin system revisited. J Intern Med 2008;264:224—36. Varagic J, Trask AJ, Jessup JA, et al. New angiotensins. J Mol Med 2008;86:663—71. Ferrario CM. New physiological concepts of the renin—angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 2010;55:445—52. ARB, angiotensin receptor II type 1 blocker; ICAM, intracellular adhesion molecule; IL, interleukin; MCP, monocyte chemoattractant protein; PAI, platelet activation inhibitor-1; SNS, sympathetic nervous system; TNF, tumour necrosis factor.474

significant effect of ACEIs on cardiac autonomic regulation as measured by baroreflex sensitivity. All patients had normal cardiac function. Anaesthesia-related hypotension was defined by SBP < 90 mm Hg. Baroreflex sensitivity was estimated after BP changes induced by injections of phenylephrine and nitro-glycerin. Anaesthesia-related hypotension occurred in nine patients in the ACEI group versus only two controls, and they found a diminished response to phenylephrine in the ACEI group. The authors determined that anaesthetic-induced hypotension is mainly an effect of decreased adrenergic vaso-constitutive response.31

A systematic review with random-effects meta-analysis (five studies; N = 434 patients) found a greater likelihood of hypo-tension requiring vasopressors at or shortly after induction of anaesthesia in the setting of preoperative RAAS antagonist administration on the day of surgery (RR 1.50, 95% CI 1.15 to 1.96). Despite this, the incidence of perioperative myocardial infarction was not significantly different between groups continuing or stopping RAAS antagonists (RR 0.41, 95% CI 0.07 to 2.55). It should be noted that this analysis was not controlled for cardiac risk factors, as data were insufficient for subgroup comparisons.22 In a subsequent large prospective observational study of 12,881 patients undergoing non-cardiac surgery, with similar cardiovascular and pulmonary comorbidities controlled by propensity score matching, the concomitant use of diuretics along with RAAS antagonists increased both intraoperative hypotension and requirement for vasopressors compared with ACEIs alone or when used in combination with calcium-channel blockers. It should be noted that all hypertensive patients were excluded from the study. There were no statistically significant differences in postoperative renal failure or myocardial ischaemia between patients receiving RAAS alone versus RAAS and diuretics.33

A recent study addressing the effect of RAAS blockade on 30-day mortality was conducted by Railton et al. They demonstrated an increase in postoperative 30-day mortality in patients using RAAS inhibitors before surgery in an observational cohort study of 883 consecutive patients undergoing elective open abdominal aortic aneurysm repair. RAAS blockers were used before surgery by 359 patients compared with 524 who did not. The overall 30-day mortality was 3.5% (31/883 patients). Analysis of 261 propensity score-matched pairs showed a 30-day mortality of 6.1% (16/261) in the patients with RAAS blockade compared with 1.5% (4/261) in the unblocked patients (OR 5.0, 95% CI 1.4 to 27; p = 0.005).38

Cardiac surgery

Most of the negative outcomes related to the use of RAAS antagonists before cardiac surgery (regardless of whether the patients undergo cardiopulmonary bypass (CPB)) are believed to be related to the development of intraoperative hypotension requiring vasopressor support33–35; however, other potential adverse outcomes include intraoperative reduction in cardiac output,30 postoperative decline in renal function,7 atrial fibrillation, and even death.3 39

Vasoplegic syndrome is a form of vasodilatory shock that can occur after CPB. In a prospective study of 145 patients undergoing CPB, two independent predictors of development of vasodilatory shock after discontinuation of CPB were identified: ejection fraction (EF) < 55% (OR 11.9, 95% CI 2.7 to 53.1; p = 0.003) and ACEI use (OR 9.1, 95% CI 2.1 to 38.8; p = 0.001). These patients responded well to AVP infusions.40 In a subsequent retrospective study (2002–2006) of 2225 adult cardiac surgery cases, Levin et al found that 577 (20.4%) developed post-CPB vasoplegic syndrome; these patients had an increased inpatient mortality and length of stay > 10 days (OR 3.30; 95% CI 1.44 to 7.57; p < 0.005). The preoperative use of ACEIs was associated with a modest increase in the risk of vasoplegia (OR 1.37, 95% CI 1.04 to 1.80; p = 0.026).38

In a study of 249 patients who underwent aortic surgery, Cittanova et al found that 61 developed postoperative renal impairment, defined as a 20% decrease in baseline glomerular filtration rate (GFR), 7 days after surgery. Chronic treatment with ACEIs was the only factor significantly associated with postoperative renal impairment even after exclusion of patients with EF < 35% (OR 2.01, 95% CI 1.05 to 3.83; p = 0.034).7

The association of hypotension with intraoperative decrease in cardiac output was described by Colson et al, who studied 16 hypertensive patients (eight receiving ACEIs, and eight receiving a combination of other antihypertensive agents) who underwent coronary artery bypass grafting (CABG) or vascular surgery. In ACEI-treated patients, the hypotension was associated with a consistent decrease in pulmonary capillary wedge pressure (–26.4%; p = 0.035) and cardiac index (–23.9%; p = 0.001), suggesting that the post-induction hypotension in patients using ACEIs is secondary to poor cardiac output during acute decreases in ventricular volume. Although the sample size was small, this study is important in that it was the first to address the effect of ACEIs on intraoperative cardiac output and to have used the same anaesthetic technique in all patients to avoid confusing variables.33

A prospective non-randomised study to address the utilisation of vasopressor therapy in patients taking ACEIs on CPB was carried out by Tuman et al. In 4501 adults undergoing elective coronary artery and/or valve surgery, they identified 519 patients taking ACEIs before surgery, and 3782 that were not. Preopera-tive ACEI use was identified as an independent risk factor for multiple (>2) vasopressor infusions after extracorporeal CPB to keep SBP > 85 mm Hg (OR = 1.53, 95% CI 1.05 to 2.25; p = 0.0301).36

Deakin et al studied 62 sequential adult patients undergoing cardiac surgery requiring hypothermic (28°C) CPB. Twenty-one patients were receiving ACEIs before surgery. Preoperative ACEI therapy was associated with a significant decrease in systemic vascular resistance during the rewarming phase of CPB (p = 0.006) and increases in post-CPB vasoactive drug requirements (RR 3.32, 95% CI 1.45 to 7.71; p = 0.01). This study is unfortunately limited by its small size, non-randomised design, and inability to identify whether the hypotension was linked to low systemic vascular resistance or low cardiac output.37

The effects of preoperative ACEI use in patients undergoing CABG without CPB (off pump) were studied by Lee et al. They compared 45 patients treated with ACEIs for at least 4 weeks before surgery with 37 patients who did not receive ACEIs. There was greater utilisation of vasoconstrictors in the ACEI group especially during anastomosis of the obtuse marginal branch of the left circumflex artery. The study was limited by its relatively small sample size, non-randomised design, and presence of other multiple confounding factors such as diabetes and hypertension which can affect haemodynamic parameters.41

Boeken et al studied 240 patients undergoing cardiac surgery (CABG or valvular) and divided them in a non-randomised fashion into three groups: group A used pre- and post-operative ACEIs; group B used preoperative ACEIs only; group C used no ACEIs. They did find a significant increase in intra- and post-operative catecholamine use in the patients using preoperative ACE (p = 0.05). In the ACEI groups, nine patients developed systemic inflammatory response syndrome compared with only two cases in group C, suggesting that the vasodilatory effect of
RAAS inhibition may predispose to ‘post-perfusion syndrome’ and systemic inflammatory response syndrome. Interestingly, four patients in group B (no postoperative ACEI use) had postoperative disturbances of the intestinal microcirculation, suggesting that the withdrawal of ACEIs in patients with chronic use may further predispose to microcirculation derangements.42

A best evidence topic review addressing whether preoperative cessation of RAAS antagonists in cardiac surgery permits avoidance of postoperative vasodilatation was performed by Raja and Fida. They initially examined 421 articles and ultimately selected three randomised controlled trials and seven large cohort and case–control studies. The authors concluded that preoperative administration of ACEIs and ARBs in patients undergoing cardiac surgery contributes to a postoperative decrease in systemic vascular resistance and vasoplegia, and that withholding ACEIs and ARBs before cardiac surgery is reasonable to avoid postoperative vasodilatation; however, the evidence supporting this decision is weak.43

Miceli et al performed a retrospective observational cohort study (1996–2008) of 10 025 patients undergoing isolated CABG. Of these, 3052 patients receiving preoperative ACEIs were matched with a control group by propensity score analysis. Patients receiving preoperative ACEIs were more likely to have an EF <50% (52.8% vs 20.2%). They found that preoperative use of ACEIs was an independent predictor of mortality (OR 2.83, 95% CI 2.19 to 3.63; p<0.0001), which was an independent risk factor for POAF (OR 1.38, 95% CI 1.07 to 1.80; p=0.009). The overall mortality was 1%. Preoperative ACEIs were associated with a doubling of the mortality risk (1.3% vs 0.7%; OR 2.00, 95% CI 1.17 to 3.42; p=0.018). The main limitations of this study are its retrospective nature; the inability to distinguish between the use of ACEIs and ARBs, and the lack of information with regard to drug dose and timing.8

Magee et al developed a predictive risk algorithm to determine the possibility of developing postoperative atrial fibrillation using a database of 19 083 patients who underwent CABG (1995–2006). Among the risk factors, the preoperative use of ACE inhibitors was associated with a modest increase in the development of POAF (OR 1.23, 95% CI 1.045 to 1.205; p<0.001). However, it should be mentioned that the algorithm had modest validation scores (receiver operating characteristic curve area of 0.72 and concordance between observed and predicted of 72.3%).39

In a recent large observational study, Rader et al evaluated the relationship of preoperative use of RAAS inhibition with ACEIs or ARBs within 24 h of surgery and the development of POAF in patients undergoing CABG. Preoperative RAAS inhibition occurred in 4795 patients versus 5757 who did not. In the patients receiving RAAS inhibition, 1725 (36%) developed POAF compared with 1908 (53%) (OR 1.13, 95% CI 1.05 to 1.25; p<0.001). However, after propensity score matching, there was no significant association between preoperative RAAS inhibition and POAF (OR 1.05, 95% CI 0.95 to 1.16; p=0.38).44

Postoperative renal failure

As described in the previous section, multiple studies have found a relationship between the preoperative use of RAAS antagonists and the development of postoperative renal failure.7 8

The effect of the chronic RAAS inhibition on postoperative renal function was addressed by Arora et al in a retrospective cohort study (2001–2005) of 1538 patients who underwent cardiac surgery. The authors confirmed by multiple regression and propensity scores model a 27.6% higher risk of postoperative acute kidney injury (AKI) associated with preoperative use of ACEIs/ARBs.45

In a retrospective study (2000–2002) of 1209 adult patients undergoing coronary artery bypass graft, valve or combined procedures, Kincaid et al found an incidence of perioperative acute renal failure of 3.5%, with a 48% incidence of mortality for the patients that developed renal failure. The most significant risk factor for development of acute renal failure was the preoperative use of ACEIs along with the intraoperative use of aprotinin (OR 2.9, 95% CI 1.4 to 5.8; p<0.0001). Interestingly, the effect of either drug alone was not significant. The proposed mechanism of this relationship is attributed to an aprotinin-mediated vasoconstriction of the afferent arteriole with subsequent reduction of the glomerular perfusion pressure in the setting of an ACEI-promoted vasodilatation of the efferent arteriole.46

Neuraxial anaesthesia

The studies described in the previous section occurred in the setting of general anaesthesia with standard pharmacological protocols. The haemodynamic effects of neuraxial anaesthesia are related to the spinal level of anaesthesia; for instance, in thoracic epidural anaesthesia, hypotension results from attenuation of efferent sympathetic drive.47

The evidence on the effects of RAAS blockade in neuraxial anaesthesia is limited and contradictory. It has been shown that, in patients with preoperative use of ACEIs, there are increased concentrations of vasopressin and norepinephrine in the early phases of spinal anaesthesia that appear to attenuate the hypotensive effect of RAAS blockade.48 49 However, multiple cases of significant hypotension and bradycardia following spinal anaesthesia in patients chronically treated with ACEIs have been reported.50–55

Until further randomised studies are carried out to further clarify the best practice, it appears safe to stop RAAS blockade before spinal anaesthesia.

EVIDENCE SUPPORTING RAAS ANTAGONISTS IN THE PERIOPERATIVE SETTING

Although the basis for withholding RAAS antagonists on the morning of surgery is to avoid the risk of initial hypotension after the induction of anaesthesia, before the study by Miceli et al8 there had been no significant adverse effects (eg, mortality) related to the use of these agents reported in the literature. It was considered that, in certain cases, the preoperative use versus discontinuation of these agents should be factored into the overall risk–benefit equation, as certain groups of patients may benefit from its continuation (eg, systolic dysfunction, uncontrolled hypertension).

As part of their Physicians’ Information and Education Resource, the American College of Physicians supports the cautious continuation of RAAS antagonists on the morning of surgery, with the caveat that euvoalaemia should be maintained.56

Some authors suggest the continuation of ACEIs in patients with congestive heart failure, as the benefit may outweigh the risks—especially since hypotensive episodes are usually responsive to volume expansion and vasoconstrictors.17 57

The most important described beneficial effects of the perioperative use of RAAS antagonists include neuroprotection, improved haemodynamic stability, decreased POAF, limited ischaemia–reperfusion injury and renal protection.
Neuroprotection
Tohmo et al described the use of preoperative enalapril as part of balanced hypotensive anaesthesia for cerebrovascular surgery.60 This is a technique in which controlled hypotension is used to minimise intraoperative bleeding and the need for transfusional support.59 Enalapril was associated with a decrease in the hypertensive response to intubation, lowered the requirements for postoperative vasodilators, and provided for more stable BP control compared with placebo.50 The authors theorised that preoperative fasting may be a more significant contributor to perioperative hypotension, and that the hypotension after induction of anaesthesia might be prevented by ensuring proper intravascular volume rather than withholding ACEIs before surgery.60

Haemodynamic stability
Sear et al measured the haemodynamic response to anaesthesia induction followed by laryngoscopy and intubation in 105 patients; 83 were already receiving one of four antihypertensive agents: ACEIs, BBs, CCBs and diuretics. Twenty-three patients were naïve to treatment. BP, cardiac output and stroke volume were monitored during induction of anaesthesia, intubation and maintenance of anaesthesia. Induction of anaesthesia caused hypotension and a decrease in cardiac output in all groups. Heart rate decreased in patients taking ACEIs and diuretics (p<0.01), and systemic vascular resistance decreased in patients taking ACEIs and β-blockers (p<0.05). BP and heart rate increased in all groups after laryngoscopy and intubation (p<0.01), as did the systemic vascular resistance in patients taking ACEIs, BBs and diuretics (p<0.02). In the group of untreated patients, the changes were similar. Comparison over time of all haemodynamic variables showed no differences between all groups.61

Some authors advocate preoperative ACEIs for all CABG patients. Although intraoperative hypotension may develop, there is a concomitant postoperative increase in cardiac output and index.62

Decreased POAF
Ozaydin et al studied the effect of preoperative administration of ACEIs or ARBs on the development of POAF in patients undergoing cardiac surgery. The study involved 128 consecutive patients (ACEIs n=49, ACEIs plus candesartan n=49, control n=30). The rate of POAF was higher in the control group (53.3%) than the ACEI (12.2% (RR 0.34, 95% CI 0.12 to 0.93; p=0.03)) or ACEI plus candesartan (10.2% (RR 0.28, 95% CI 0.09 to 0.83; p=0.02)) group.64

White et al evaluated the impact of preoperative ACEI or ARB use in the development of POAF after cardiac surgery (CABG or valvular surgery) in a cohort of 538 patients (51.8%; N=175 received preoperative ACEIs or ARBs). The authors did not find an association between preoperative use of ACEIs/ARBs and reduction in POAF (adjusted OR 0.71, 95% CI 0.42 to 1.20). They proposed that a larger number of patients would be needed to further evaluate the impact of preoperative ACEI or ARB use and POAF.65

A recent meta-analysis of 23 randomised control trials with 87,048 patients showed that RAAS antagonists decreased the OR for AF by 33% (p<0.00001), especially among patients with heart failure and those with hypertension and left ventricular hypertrophy. However, this meta-analysis was not designed in the perioperative context.66

The anti-arrhythmogenic potential of RAAS antagonists may be due to a sympatholytic effect or the attenuation of electrical and/or structural remodelling. RAAS antagonists also have antihypertensive properties with subsequent decrease in atrial and left ventricular end diastolic pressure. In addition, RAAS antagonists help prevent hypokalaemia.67

Protection against ischaemia—reperfusion injury
Boldt et al randomised 88 patients undergoing CABG into four groups of 22 patients each, to receive intravenous enalapril, enoximone (a phosphodiesterase inhibitor), clonidine or placebo (normal saline). The patients who received enalapril after induction of anaesthesia and before CPB had lower levels of cardiac enzyme release, suggesting that RAAS antagonists may have a cardioprotective effect against ischaemia–reperfusion injury.68 A similar finding was obtained by Benedetto et al in patients undergoing CABG with CPB. They compared 245 patients who received preoperative ACEIs with 256 patients who did not; the patients receiving preoperative ACE inhibitors had lower postoperative troponin I concentrations (1.6 ng/ml (95% CI 1.05 to 3.4) vs 2.4 ng/ml (95% CI 1.13 to 6.10); p=0.0006). Although not significant, there was also a decreased rate of postoperative myocardial infarction (2.0% vs 4.2%; p=0.25) in patients receiving periprojective ACEIs.69

Licker et al allocated 20 patients into two groups: 11 patients received intravenous enalapril 50 µg/kg and nine patients received normal saline at the time of anaesthesia induction for aortic surgery. After infrarenal aortic cross-clamping, the investigators found that the preoperative administration of enalapril was associated with enhanced systemic oxygen delivery, improved splanchnic perfusion and improved GFR 24 h after surgery.70

Renal protection
Temporary withdrawal of RAAS antagonists may be expected to increase RAAS activity. The potential loss of BP control may be at the expense of impaired regional circulation as demonstrated by several studies that show the preservation and even improvement of renal function in patients receiving ACEIs before surgery.17

In a randomised double-blind study, Colson et al compared short-term (2 days) preoperative treatment with captopril with placebo in 18 patients undergoing CABG. Captopril-treated patients had improved renal plasma flow and GFR during bypass compared with placebo-treated patients.71

In a study of 556 patients by Benedetto et al, the effect of preoperative ACEIs on AKI (defined as a postoperative decrease in GFR of >50% from the preoperative value) was evaluated after CABG with CPB. Of the 556 patients, 281 received ACEI inhibitors before surgery. The incidence of AKI was 6.4% in the ACEI group and 12.2% in the control group (p=0.02). The incidence of AKI requiring dialysis was 2.4% in the ACEI group and 6.3% in the controls (p=0.03). The authors found that preoperative ACEIs was associated with a decreased incidence of postoperative AKI (OR 0.48, 95% CI 0.23 to 0.77; p=0.04) after on-pump CABG surgery.72

Adverse consequences of RAAS antagonist cessation
The benefit of ACEIs in patients with systolic heart failure is well documented. Groban and Butterworth recommend that...
ACEIs should be continued before surgery in patients with heart failure in both cardiac and non-cardiac surgery, as the benefits outweigh the potential risks. Careful expansion of intravascular volume should occur before induction of anaesthesia, and any brief episodes of hypotension should be treated with sympathomimetics. In the case of refractory hypotension either during non-cardiac surgery or on weaning from CPB during cardiac surgery, vasopressin or vasopressin antagonists can be used. Careful selection of anaesthetic agents less likely to cause hypotension (e.g., etomidate) as well as sequential administration of the anaesthetic agents may prevent or attenuate the hypotensive response to anaesthesia. An important consideration in the heart failure patient is the concurrent use of multiple drugs, including antiarrhythmics such as amiodarone. Mackay et al reported two cases of refractory hypotension in anaesthetised patients under CPB who received amiodarone in combination with ACE.

There is very limited evidence about the perioperative consequences of withdrawing RAAS antagonists in the setting of heart failure with preserved EF (diastolic heart failure). Careful haemodynamic monitoring of these patients, including strict BP control, is recommended. It is important to avoid hypertensive crises which may precipitate the development of flash pulmonary oedema.

OTHER RAAS ANTAGONISTS—THE DIRECT RENIN INHIBITORS

Because renin controls the rate-limiting step in the RAAS cascade, the blockage of its receptors is an optimal target for RAAS suppression. Aliskiren is the first direct renin inhibitor approved by the Food and Drug Administration for treating hypertension. It has a long half-life (30–40 h), as well as an increased renal vasodilatory effect compared with ACEIs and ARBs. However, owing to its low oral bioavailability (up to 90% excreted unchanged in faeces), its terminal half-life is 24 h. It is a second-line agent and generally considered a weak antihypertensive. It should preferably be used in combination with natriuretic agents or ARBs. No long-term outcome data on its use are available at this time. Consequently, there are no data to guide its use in the perioperative setting. However, we hypothesise that, given its pharmacological properties, the last dose should be given at least 24 h before scheduled surgery, and clinical trials should be pursued to address its effect on perioperative BP control and outcomes.

OTHER RAAS ANTAGONISTS—THE ALDOSTERONE ANTAGONISTS

The final pathway in RAAS is the stimulation of aldosterone production and release from the zona glomerulosa of the adrenal cortex. This hormone is a mineralocorticoid that increases the renal absorption of water and sodium and enhances renal potassium excretion. Its final effect is an increase in circulating blood volume. Elevated concentrations of aldosterone are associated with increased mortality in heart failure. In patients with cirrhosis and portal hypertension, elevated concentrations of aldosterone are associated with the development of ascites. The pathophysiological mechanisms of aldosterone in heart failure and portal hypertension are beyond the scope of this review. However, given its deleterious effect in heart failure, aldosterone blockade has emerged as a mainstay of treatment in advanced heart failure (New York Heart Association class III and IV). Also, because of its hyperkaluric properties, the use of aldosterone blockers are commonly used as ‘potassium-sparing’ diuretics.

Main messages

- The renin–angiotensin–aldosterone system (RAAS) antagonists include: ACE inhibitors (ACEIs), angiotensin 1 receptor blockers (ARBs) and aliskiren (direct renin inhibitor), as well as the aldosterone antagonists (spironolactone, eplerenone).
- The preoperative use of RAAS antagonists is associated with significant hypertensive episodes after induction of anaesthesia requiring the use of systemic vasopressor drugs.
- Recently, increased morbidity and mortality have been shown in patients undergoing coronary artery bypass grafting who continue ACE inhibitors before surgery.
- In patients who are using RAAS antagonists and will undergo surgery, RAAS should be withheld one half-life before induction of anaesthesia.
- If it is not possible to withhold RAAS antagonists before induction of anaesthesia (e.g., emergency surgery), the anaesthesiologist should maintain adequate intravenous volume and perform careful haemodynamic monitoring.

There are two known aldosterone antagonists—spironolactone and eplerenone. The first one is well known as a diuretic agent, and the second is used in patients who develop heart failure after myocardial infarction, but may also be used in patients with heart failure of any aetiology who are intolerant of spironolactone. The evidence supporting the use or discontinuation of spironolactone or eplerenone in the perioperative setting is scant except for the recommendation of continuation of these agents in patients undergoing resection of aldosterone-producing tumours.

Given their mineralocorticoid antagonist activity, as well as the diuretic effect of spironolactone, we recommend withholding these agents before surgery to minimise intraoperative hypotension as well as electrolyte derangement, especially hyperkalaemia.

CONCLUSIONS AND RECOMMENDATIONS

The use of RAAS antagonists (ACEIs/ARBs) has been associated with a variable incidence of intraoperative hypotension after induction of anaesthesia; at the present time, there is growing evidence linking the preoperative use of these agents with postoperative adverse effects including worsening of renal function and even death.

In certain cases (e.g., uncontrolled hypertension, systolic dysfunction), continuation of RAAS antagonists may be...
THE USE OF RAAS ANTAGONISTS IN NON-CARDIAC SURGERY

1. The drug aliskiren is a direct renin inhibitor.
2. The vasodilatory actions of RAAS antagonists involve multiple mechanisms, which include direct sympathetic blockade, increased bioavailability of vasodilators such as bradykinin, nitric oxide and prostacyclins, inhibition of the direct and indirect vasoconstrictor effects of angiotensin II, and reduced secretion of aldosterone and antidiuretic hormone leading to a decrease in salt and water reabsorption by the kidney.

The vasodilatory actions of RAAS antagonists involve multiple mechanisms, which include direct sympathetic blockade, increased bioavailability of vasodilators such as bradykinin, nitric oxide and prostacyclins, inhibition of the direct and indirect vasoconstrictor effects of angiotensin II, and reduced secretion of aldosterone and antidiuretic hormone leading to a decrease in salt and water reabsorption by the kidney. Given the wide distribution of ACE in the body, the RAAS antagonists have wide-ranging effects, secondary to the inhibition of various angiotensin peptides as well as both renin and pro-renin receptors with endocrine, paracrine and intracrine functions, which in turn regulate diverse physiological functions.

Temporary withdrawal of RAAS antagonists may prevent or attenuate intraoperative hypotension and hypovolaemia. The current practice in our institution is to avoid the use of ACEIs and ARBs on the morning of surgery.

REFERENCE

REFERENCES


Pose Reina A, Pina Seijo M, Baltar Martinez de la Riva A. Severe hypotension during spinal anesthesia induced by angiotensin-converting enzyme inhibitors (In Spanish). *Med Clin (Barc)* 2000; 130:159.


Smith J, Jackson I. Beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers: should they be stopped or not before ambulatory anaesthesia? *Curr Opin Anaesthesiol* 2010; 23:867–90.


